BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

Less than a week after FDA granted Emergency Use Authorization to Gilead’s COVID-19 therapy remdesivir, Japan approved the antiviral as Veklury. Separately, a global plasma coalition sealed a deal with NIH, and three Chinese biotechs...
BioCentury | Feb 14, 2020

On heels of reimbursement, Innovent raises $303M to ready Tyvyt rollout

Within one month of its stock reaching an all-time high, Innovent priced its second follow-on offering on the Hong Kong exchange early Thursday, raising HK$2.4 billion ($303.2 million) to expand manufacturing capacity in preparation for...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BC Extra | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic  FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with Type II diabetes and heart disease....
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 11, 2019
Financial News

Local demand high for Alphamab Oncology’s Hong Kong IPO

Local investors secured additional shares as Alphamab Oncology Ltd. (HKEX:9966) priced its IPO on the Hong Kong stock exchange Wednesday in a deal that raised HK$1.8 billion ($233.8 million) and valued the company at HK$9.1...
BC Extra | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

Medicines Co. mum on Novartis takeout rumor  The Medicines Co. (NASDAQ:MDCO) declined to comment to BioCentury on a Bloomberg report that said Novartis AG (NYSE:NVS; SIX:NOVN) is among several companies exploring an acquisition of the...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Oct 4, 2019

Biotechs likely to flood IPO market ahead of 2020 election

Buysiders and bankers expect a flood of IPOs and a stock picker's market in 4Q19 amid a continued run of sector underperformance that is only expected to get worse in 2020. As macro pressures continue...
BC Extra | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to list on the exchange’s biotech chapter in four months Wednesday, raising HK$3.2 billion ($409.9 million) in an IPO that...
Items per page:
1 - 10 of 47